Agios Pharmaceuticals shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $44 to $53. Also, Goldman Sachs maintained a Neutral rating on the stock and raised its price target from $33 to $53.
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals shares are trading higher after RBC Capital and Goldman Sachs raised their price targets for the stock. RBC Capital maintained an Outperform rating and increased the price target from $44 to $53, while Goldman Sachs maintained a Neutral rating and raised the price target from $33 to $53.
June 04, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agios Pharmaceuticals shares are trading higher following positive analyst actions. RBC Capital maintained an Outperform rating and raised its price target from $44 to $53. Goldman Sachs maintained a Neutral rating and also raised its price target from $33 to $53.
The stock price of Agios Pharmaceuticals is likely to rise in the short term due to the increased price targets from both RBC Capital and Goldman Sachs. The Outperform rating from RBC Capital is particularly positive, indicating strong confidence in the stock's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100